Drug intelligence / Profile preview

Xuzhou Medical Univ. TLR7 compound 11a

Development stage: Unknown
Lead developer: Xuzhou Medical University

Overview

Xuzhou Medical Univ. TLR7 compound 11a: sourced facts only. name: "SPR analysis confirmed that 11a could bind to TLR7 protein with an affinity of 7.06 μM." [PMID:38865744]; target: "SPR analysis confirmed that 11a could bind to TLR7 protein with an affinity of 7.06 μM." [PMID:38865744]; developer: "Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China." [PMID:38865744]

Targets

TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on Xuzhou Medical Univ. TLR7 compound 11a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xuzhou Medical Univ. TLR7 compound 11a.